EDITORIAL
Reference centers for interstitial lung diseases
 
More details
Hide details
1
Academic Department of Pneumonology, Interstitial Lung Diseases Unit, Medical School, National and Kapodistrian University of Athens; Hospital for Diseases of the Chest “Sotiria”, Greece
 
 
Publication date: 2021-06-17
 
 
Corresponding author
Demosthenes Bouros   

Medical School, University of Athens, Academic Department of Pneumonology, Hospital for Diseases of the Chest “Sotiria”, 152 Messogion Ave. , Athens 11527, Greece
 
 
Pneumon 2016;29(1):15-17
 
CONFLICTS OF INTEREST
We have no conflict of interest to declare
 
REFERENCES (21)
1.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J RespirCrit Care Med 2002;165:277-304.
 
2.
Travis WD, Costabel U, Hansell DM, et al; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2013; 188:733–48.
 
3.
Raghu G, Collard RH, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
 
4.
Raghu G, Chen SY, Yeh WS et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med 2014;2:566-72.
 
5.
Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review. Eur Respir J 2015;46:795-806.
 
6.
Bouros D. Idiopathic Pulmonary Fibrosis: The dawn of a new era. Pneumon 2014;27:117.
 
7.
Bouros D. Pirfenidone for idiopathic pulmonary fibrosis. Lancet 2011; 377:1727-9.
 
8.
King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2083–92.
 
9.
Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370:2071–82.
 
10.
Idiopathic Pulmonary Fibrosis Clinical Research Network; Raghu G, Anstrom KJ, King TE Jr, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
 
11.
Bouros D. Current therapy of idiopathic pulmonary fibrosis: primum non noccere! Pneumon 2012;25:256-8.
 
12.
Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998;157:199–203.
 
13.
Lynch DA, Godwin JD, Safrin S, et al; Idiopathic Pulmonary Fibrosis Study Group. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J RespirCrit Care Med 2005; 172:488–93.
 
14.
Watadani T, Sakai F, Johkoh T, et al. Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology 2013;266:936-44.
 
15.
Walsh SL, Calandriello L, Sverzellati N, et al. Interobserver agreement for the ATS/ERS/JRS/ALAT criteria for a UIP pattern on CT. Thorax 2016;71:45-51.
 
16.
Nicholson AG, Addis BJ, Bharucha H, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax 2004;59:500-5.
 
17.
Kreider ME, Hansen-Flaschen J, Ahmad NN, et al. Complications of video-assisted thoracoscopic lung biopsy in patients with interstitial lung disease. Ann Thorac Surg 2007;83:1140–44.
 
18.
Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg 2008;34:878–81.
 
19.
Tzilas V, Bouros D. Inherent weaknesses of the current ICD coding system regarding idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1194-6.
 
20.
Kaunisto J, Kelloniemi K, Sutinen E, et al. Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis. BMC Pulm Med 2015;15:92.
 
21.
Lamas DJ, Kawut SM, Bagiella E, et al. Delayed access and survival in idiopathic pulmonary fibrosis: a cohort study. Am J Respir Crit Care Med 2011;184:842–7.
 
eISSN:1791-4914
ISSN:1105-848X
Journals System - logo
Scroll to top